Global Large Volume Wearable Injectors Market Report 2021-2035: Emphasis on the Emergence of Patient-Centric, Convenient, Cost-Effective and User-Friendly Wearable Drug Delivery Solutions

News provided by

Jan 10, 2022, 13:30 ET

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- The "Large Volume Wearable Injectors Market by Type of Device, Usability, Therapeutic Area, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.

The "Large Volume Wearable Injectors Market" report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next fifteen years.

It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2021-2035.

Over the last few years, the industry has seen the emergence of advanced drug delivery devices, such as wearable injectors, autoinjectors and pen injectors. These are the self-injection devices that have the capability of producing a sustained therapeutic effect, thereby improving patient adherence and efficacy of treatments. Such practices also allow reductions in costs and enable the optimal usage of healthcare resources.

The approval of novel drugs, specifically biologics that have high viscosity and cannot be administered in lower volume, has further led to an increased demand for advanced drug delivery devices. As a result, medical device industry has come up with several large volume wearable injectors suitable for the delivery of such molecules. These innovative injection systems offer numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, along with minimal or no risk of needlestick injuries.

The report features detailed transcripts of discussions held with the following individuals:

Mark Banister (CEO, Medipacs/RxActuator)
Michael Hooven (CEO, Enable Injections)
Jesper Roested (CEO, Subcuject)
Pieter Muntendam (former President and CEO, scPharmaceuticals)
Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
Graham Reynolds (former Vice President and General Manager, Biologics, West Pharmaceutical Services)
(Vice President, Ypsomed)
Eric Chappel (R & D Project Manager, Debiotech)
Mindy Katz (Vice President, Marketing and Alliance Management, Sorrel Medical)

Key Questions Answered

Who are the leading large volume wearable device developers?
Which are the popular types of wearable devices available in this market?
What are the key challenges faced by stakeholders engaged in the development of large volume wearable injectors?
What types of partnership models are commonly being adopted by stakeholders in this industry?
Who are the key investors in this domain?
How has the intellectual property landscape of wearable injectors evolved over the years?
Which drug candidates are likely to be considered for administration via wearable injectors?
What factors are likely to influence the evolution of this market?
Which geographies are the most active in conducting clinical trials on large volume drug device combinations?
How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Large Volume Wearable Injectors For Non-Insulin Drugs: Current Market Landscape

5. Large Volume Drug Device Combinations: Current Market Landscape

6. Large Volume Wearable Injectors For Insulin Drugs: Current Market Landscape

7. Product Competitiveness Analysis

8. Large Volume Wearable Injectors: Company Profiles

9. Drug-Device Combinations: Tabulated Profiles

10. Partnerships And Collaborations

11. Key Acquisition Targets

12. Patent Analysis

13. Large Volume Wearable Injectors: Likely Drug Candidates

14. Clinical Trial Analysis

15. Funding And Investment Analysis

16. Case Study: Role Of Contract Manufacturing Organizations In Device Development Supply Chain

17. Regulatory And Reimbursement Landscape For Medical Devices

18. Market Sizing And Opportunity Analysis

19. SWOT Analysis

20. Executive Insights

21. Concluding Remarks

22. Appendix 1: Tabulated Data

23. Appendix 2: List Of Companies And Organizations

Companies Mentioned

3E Bioventures
3M
5AM Ventures
Abbott
AbbVie
AbGenomics
Ablynx
Acceleron Pharma
ADC Therapeutics
Adrenomed
Aduro BioTech
Advaxis
Aeglea BioTherapeutics
Aesica Pharmaceuticals
Aetna
Affibody
Affimed
Agenus
AgonOx
Akesobio Australia
Alder BioPharmaceuticals
Alector
Alexion Pharmaceuticals
Alkahest
Alkermes
Allakos
Allergan
Allozyne
Alnylam Pharmaceuticals
AlphaCore Pharma
Altor BioScience
Ambrx
Amgen
Amicus Therapeutics
Amphivena Therapeutics
Amplyx Pharmaceuticals
AMSL Diabetes
Angiochem
Animas Corporation
Antaros Medical
Apellis Pharmaceuticals
Aptevo Therapeutics
Argenx
Argos Therapeutics
ArmaGen
ARMO BioSciences
Aronora
ArrowMark Partners
Arthurian Life Sciences
Asante Solutions
Ascensia Diabetes Care
Asklepion Pharmaceuticals
Astellas Pharma
AstraZeneca
Atridia
Axon Neuroscience
Baril
Basilea Pharmaceutica
Bastian Solutions
Baxter International
Bayer
Bayhill Therapeutics
Becton Dickinson
BeiGene
Beijing Dongfang Biotech
Bespak
Beta Bionics
Bigfoot Biomedicals
BioArctic
BIOCAD
Biogen
BioIntegrator
Bioject Medical Technologies
BioMarin Pharmaceutical
Bioniz Therapeutics
BioNTech
Bio-Path Holdings
Biotest Pharmaceuticals
Bio-Thera Solutions
Blackstone Life Sciences
BOCIG
Boehringer Ingelheim
Boston Pharmaceuticals
Calando Pharmaceuticals
Calibra Medical
Cam Med
CANbridge Life Sciences
Cancer Advances
Capital District Physicians' Health Plan
Cara Therapeutics
Cardiac Pacemakers
Cardiome Pharma
Care Innovations
Catalyst Biosciences
CCBio
Cecelia Health
Celgene
Celldex Therapeutics
CEL-SCI
CeQur
Chimerix
CHO Pharma
Chugai Pharmaceutical
Cincinnati Children's Hospital
CincyTech
Cintrifuse
Cleveland BioLabs
Cleveland Clinic
Cormorant Asset management
Conjupro Biotherapeutics
Consort Medical (Bespak Injectables)
ContraFect
ConvaTec
Cordant Group
Cormorant Asset Management
Cour Pharmaceutical Development
Credit Suisse Entrepreneur Capital
CStone Pharmaceuticals
CureTech
CytoDyn
Daikyo Seiko
Datwyler
Debiotech
Deka
Dekkun
Delta-Fly Pharma
Dendreon
Dexcom
Diabeloop
DreaMed Diabetes
Duke Clinical Research Institute
E3D Elcam Drug Delivery Devices
EG GILERO
Eisai
Eitan Medical
Eli Lilly
Elusys Therapeutics
EMD Serono
Emergent BioSolutions
Enable Injections
Endeavour Vision
Endocyte
EnGeneIC
EoFlow
EpicentRx
Eris Lifesciences
Eventide
EVER Pharma
Evidation Health
F2G
Fabrico
Farallon Capital
Federated Hermes Kaufmann Funds
Ferring Pharmaceuticals
FibroGen
Fitbit
Five Prime Therapeutics
Flex
Galaxy Biotech
Galena Biopharma
Genentech
GENERON
GeneScience Pharmaceuticals
Genexine
Genzyme
Gerresheimer
Gilead Sciences
Glenmark Pharmaceuticals
Gliknik
Glooko
GMS Capital
Guangzhou Cellprotek Pharmaceutical
HAL Allergy
Halozyme Therapeutics
Hanmi Pharmaceutical
Haselmeier
Hastings
Health Innovations
HealthPrize Technologies
Helsinn Healthcare
Huabo Biopharm
Huons
IBM Watson
Idea Bridge
ImClone Systems
Immatics Biotechnologies
Immune Response BioPharma
ImmunGene
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
Implicit Bioscience
Incuron
Incyte
INKEF Capital
Innate Pharma
Innovent Biologics
Inovio Pharmaceuticals
Insight Product Development
Insulet
iNtRON Biotechnology
Invest-NL
IO Biotech
iOMEDICO AG
Ionis Pharmaceuticals
Ipsen
iSense CGM
ISU ABXIS
Janssen
Janus Capital
Janus Henderson
Jeffrey BrewerBryan Mazlish
Jerini
JHL Biotech
Jiangsu Hengrui Medicine
Jiangsu T-Mab Biopharma
Johnson & Johnson
Jounce Therapeutics
KaloBios Pharmaceuticals
Kingdon Capital
Kissei Pharmaceutical
Klue
Kreos Capital.
Kura Oncology
Kyowa Hakko Kirin
Labrys Biologics
LB investments
LEO Pharma
Levicept
Life Science Partner
LifeSci Venture Partners
Livongo
Loxo Oncology
LSP
Lundbeckfond Ventures
MabVax Therapeutics
MacroGenics
Madryn Asset Management
MedImmune
Medipacs
Medtronic
Medtrum Technologies
Menarini Diagnostics
Merck
Mereo BioPharma
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Merz Pharma
Millennium Pharmaceuticals
MiNA Therapeutics
miRagen Therapeutics
Mitsubishi Tanabe Pharma Corporation
Mode AGC
Moderna Therapeutics
Molecular Partners
Molecular Templates
Molex
MolMed
Montagu Private Equity
MorphoSys
Morphotek
MOVI
MTD Micro Moldings
mySugr
NanoPass Technologies
NantBioScience
National Institutes of Health
Naurex
Navidea Biopharmaceuticals
Nemera
Neogenix Oncology
Neon Therapeutics
NeuroDerm
National Institute of Diabetes and Digestive and Kidney Diseases
Noble
Nordic Bioscience
Nordic Infucare
Northern Biologics
Novartis Pharmaceuticals
Novimmune
NOVO Engineering
Novo Nordisk
Nuokai Capital
Nutrino
NZMS Diabetes
OBI Pharma
Octapharma
Ohio Innovation Fund
Omeros
Oncology Venture
OncoMed Pharmaceuticals
OncoPep
Oncopeptides
Oncternal Therapeutics
Oncurious
Optimer Pharmaceuticals
OrbiMed
OSE Immunotherapeutics
Otsuka Pharmaceutical
Owen Mumford
Oxford Finance
Paion UK
Panacea Pharmaceuticals
Perceptive Advisors
PercuSense
Pfizer
PharmaMar
Pharmapack
PharmaSens
PhaseBio Pharmaceuticals
Phillips Medisize
Philogen
Phosplatin Therapeutics
Pierre Fabre
Pique Therapeutics
Polaris Group
Polyphor
Prescient Therapeutics
Prestige BioPharma
Promedior
Prometheus Laboratories
Protalix Biotherapeutics
Proven Process Medical Devices
Quadrant Capital Advisors
Quest PharmaTech
Quintessence Biosciences
RAUMEDIC
Raymond James
Recipharm
Recro Pharma
Regeneron Pharmaceuticals
REM Systems
REMD Biotherapeutics
Resolve Therapeutics
rEVO Biologics
Rhythm Pharmaceuticals
Roche
Roehr pharmaceuticals
R-Pharm
RTW
Rubin Medical
RxActuator
Sagentia
Samsung Bioepis
Samsung Electronics
Sandoz
Sanofi
Santarus
Saol Therapeutics
Savient Pharmaceuticals
Schroder and Bank
scPharmaceuticals
Seattle Genetics
Selecta Biosciences
Selexys Pharmaceuticals
Senseonics
Sensile Medical
Senvest Capital
Sequoia China
Serina Therapeutics
SFC Fluidics
Shire
SHL Medical
SMC
Smile Group
Smiths Medical
Soleus Capital Management
Sonceboz
SOOIL Development
SPARK Strategic Ideas
SQ Innovation
SteadyMed Therapeutics
Stealth BioTherapeutics
Stemline Therapeutics
Stevanato Group
Subcuject
Sumitomo Dainippon Pharma
Sun Pharma
Sunovion Pharmaceuticals
SVB Leerink
Swissfillon
SymBio Pharmaceuticals
Symphogen
Synectic
Synermore Biologics
Syntimmune
Syros Pharmaceuticals
TaiMed Biologics
Taiwan Liposome Company
Takeda Pharmaceutical
Tandem Diabetes Care
Tanvex BioPharma
Tarveda Therapeutics
Teva Pharmaceutical
TG Therapeutics
Theras Group
Tolero Pharmaceuticals
TRACON Pharmaceuticals
Translational Sciences
Triplejump
TRITECH BioMed
Turnstone Biologics
Tyndall National Institute
TypeZero Technologies
Unilife
Union Chimique Belge (UCB)
United BioPharma
United Therapeutics
Vaccinex
Vaccinogen
Valetritas
Valtronic
vasopharm BIOTECH
Verily Life Sciences
Vetter Pharma
VI Partners
ViCentra
ViiV Healthcare
Visionnaire Ventures
Visterra
Vivozon
Weibel CDS
Welldoc
West Pharmaceutical Services
Wipro
Wockhardt
Woodford Investment Management LLP
Xbiotech
Xencor
XOMA
Ypsomed
Zafgen
Zollner
Zuellig Pharma

For more information about this report visit https://www.researchandmarkets.com/r/7a0srm

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets